High risk of death in elderly patients with extensive bullous pemphigoid

Archives of Dermatology

Volumn 134, Issue 4, 1998, Pages 465-469

  Roujeau, Jean Claude ^a,d   Lok, Catherine ^b   Bastuji Garin, Sylvie ^a   Mhalla, Sami ^a   Enginger, Véronique ^c   Bernard, Philippe ^c  

^a UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT;

AGED; ARTICLE; BULLOUS SKIN DISEASE; CORTICOSTEROID THERAPY; DISEASE SEVERITY; FEMALE; GERIATRIC PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MORTALITY; ORAL DRUG ADMINISTRATION; PEMPHIGOID; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; AGING; COHORT STUDIES; FEMALE; HUMANS; MALE; MULTIVARIATE ANALYSIS; PEMPHIGOID, BULLOUS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 0031957997     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.134.4.465     Document Type: Article

References (17)

1. Bernard P. Vaillant L, Labeille B, et al. Incidence and distribution of 131:48-52.
2. Korman N. Bullous pemphigoid. J Am Acad Dermatol. 1987;16-907-924
3. Ahmed AR, Newcomer VD. Clinical features. Clin Dermatol. 1987;5:6-12
4. Savin JA. The events leading to the death of patients with pemphigus and pemphigoid. Br J Dermatol. 1979;101:521-534.
5. Savin JA. Some factors affecting the prognosis in pemphigus vulgaris and pemphigoid. Br J Dermatol. 1981;104:415-420.
6. Ahmed AR, Maize JC, Provost TT. Bullous pemphigoid: clinical and immunologic follow-up after successful therapy. Arch Dermatol. 1977;113:1043-1046.
7. Burton JL, Harman RMM, Peachey RDG, Waring RP. Azathioprine plus prednisone in treatment of pemphigoid. BMJ. 1978,2:1190-1191.
8. Bernard P, Venot J, Rommel A, Bonnetblanc JM, Texier L. Pemphigoide bulleuse: étude du pronostic á propos de 57 observations. Semin Hop. 1986;62:1229-1232.
9. Milligan A, Hutchinson PE. The use of chlorambucil in the treatment of bullous pemphigoid. J Am Acad Dermatol. 1990;22:796-801.
10. Venning VA, Wojnarowska F. Lack of predictive factors for the clinical course of bullous pemphigoid. J Am Acad Dermatol. 1992;26:585-589.
11. Bernard P, Enginger V, Venot J, Bedane C, Bonnetblanc JM. Pronostic vital de la pemphigoide, analyse d'une cohorte de 78 malades. Ann Dermatol Venereol. 1995;122:751-757.
12. Zillikens D, Wever S, Weidenthaler-Barth B, Hashimoto T, Bröcker EB. Incidence of subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 1995;131:957-958.
13. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129:49-53.
14. Daguet F. Le bilan demographique du siécle. In: Données Sociales 1996, la Société Française. Paris, France: Institut National de la Statistique et Etudes Economiques; 1996:12-21.
15. Thomas TP. The complications of systemic corticosteroid therapy in the elderly. Gerontology. 1984;30:60-65.
16. Westerhof W. Treatment of bullous pemphigoid with topical clobetasol propionate. J Am Acad Dermatol. 1989;20:458-461.
17. Auger M, Bouscarat F, Picard-Dahan C, et al. Traitement de la pemphigoide par dermocorticoides. Ann Dermatol Venereol. 195;122(suppl):S21-S22.